Selected research
Industry Research
Anthracycline Anticancer Drugs Industry Research Report 2026
Market perspective
The global Anthracycline Anticancer Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Anthracycline Anticancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Anthracycline Anticancer Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Anthracycline Anticancer Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Anthracycline Anticancer Drugs include Ebewe Pharma, Sicor Societa, Beijing Union Pharmaceutical, Hisun Pharmaceutical, Hanhui Pharmaceuticals, Pfizer, Jinyuan Pharmaceutical, Lingnan Pharmaceutical and Pude Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Anthracycline Anticancer Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Anthracycline Anticancer Drugs Market by Company
Ebewe Pharma
Sicor Societa
Beijing Union Pharmaceutical
Hisun Pharmaceutical
Hanhui Pharmaceuticals
Pfizer
Jinyuan Pharmaceutical
Lingnan Pharmaceutical
Pude Pharmaceutical
CSPC OUYI Pharmaceutical
Main Luck Pharmaceuticals
New Time Pharmaceutical
Anthracycline Anticancer Drugs Segment by Type
Aclarithromycin
Adriamycin
Pirarubicin
Epirubicin
Daunorubicin
Others
Anthracycline Anticancer Drugs Segment by Application
Stomach Cancer
Soft Tissue Sarcoma
Breast Cancer
Lymphoma
Acute Leukemia
Others
Anthracycline Anticancer Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anthracycline Anticancer Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anthracycline Anticancer Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anthracycline Anticancer Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Anthracycline Anticancer Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Anthracycline Anticancer Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Anthracycline Anticancer Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Aclarithromycin
- Adriamycin
- Pirarubicin
- Epirubicin
- Daunorubicin
- Others
Applications
- Stomach Cancer
- Soft Tissue Sarcoma
- Breast Cancer
- Lymphoma
- Acute Leukemia
- Others
Companies covered
- Ebewe Pharma
- Sicor Societa
- Beijing Union Pharmaceutical
- Hisun Pharmaceutical
- Hanhui Pharmaceuticals
- Pfizer
- Jinyuan Pharmaceutical
- Lingnan Pharmaceutical
- Pude Pharmaceutical
- CSPC OUYI Pharmaceutical
- Main Luck Pharmaceuticals
- New Time Pharmaceutical
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Anthracycline Anticancer Drugs Market Size (2021-2032)
- 2.2.2 Global Anthracycline Anticancer Drugs Sales (2021-2032)
- 2.2.3 Global Anthracycline Anticancer Drugs Market Average Price (2021-2032)
- 2.3 Anthracycline Anticancer Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Aclarithromycin
- 2.3.3 Adriamycin
- 2.3.4 Pirarubicin
- 2.3.5 Epirubicin
- 2.3.6 Daunorubicin
- 2.3.7 Others
- 2.4 Anthracycline Anticancer Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Stomach Cancer
- 2.4.3 Soft Tissue Sarcoma
- 2.4.4 Breast Cancer
- 2.4.5 Lymphoma
- 2.4.6 Acute Leukemia
- 2.4.7 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Anthracycline Anticancer Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Anthracycline Anticancer Drugs Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Anthracycline Anticancer Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Anthracycline Anticancer Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Anthracycline Anticancer Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Anthracycline Anticancer Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Anthracycline Anticancer Drugs, Product Type & Application
- 3.8 Global Manufacturers of Anthracycline Anticancer Drugs, Established Date
- 3.9 Global Anthracycline Anticancer Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Ebewe Pharma
- 4.1.1 Ebewe Pharma Company Information
- 4.1.2 Ebewe Pharma Business Overview
- 4.1.3 Ebewe Pharma Anthracycline Anticancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Ebewe Pharma Anthracycline Anticancer Drugs Product Portfolio
- 4.1.5 Ebewe Pharma Recent Developments
- 4.2 Sicor Societa
- 4.2.1 Sicor Societa Company Information
- 4.2.2 Sicor Societa Business Overview
- 4.2.3 Sicor Societa Anthracycline Anticancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sicor Societa Anthracycline Anticancer Drugs Product Portfolio
- 4.2.5 Sicor Societa Recent Developments
- 4.3 Beijing Union Pharmaceutical
- 4.3.1 Beijing Union Pharmaceutical Company Information
- 4.3.2 Beijing Union Pharmaceutical Business Overview
- 4.3.3 Beijing Union Pharmaceutical Anthracycline Anticancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Beijing Union Pharmaceutical Anthracycline Anticancer Drugs Product Portfolio
- 4.3.5 Beijing Union Pharmaceutical Recent Developments
- 4.4 Hisun Pharmaceutical
- 4.4.1 Hisun Pharmaceutical Company Information
- 4.4.2 Hisun Pharmaceutical Business Overview
- 4.4.3 Hisun Pharmaceutical Anthracycline Anticancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Hisun Pharmaceutical Anthracycline Anticancer Drugs Product Portfolio
- 4.4.5 Hisun Pharmaceutical Recent Developments
- 4.5 Hanhui Pharmaceuticals
- 4.5.1 Hanhui Pharmaceuticals Company Information
- 4.5.2 Hanhui Pharmaceuticals Business Overview
- 4.5.3 Hanhui Pharmaceuticals Anthracycline Anticancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Hanhui Pharmaceuticals Anthracycline Anticancer Drugs Product Portfolio
- 4.5.5 Hanhui Pharmaceuticals Recent Developments
- 4.6 Pfizer
- 4.6.1 Pfizer Company Information
- 4.6.2 Pfizer Business Overview
- 4.6.3 Pfizer Anthracycline Anticancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Pfizer Anthracycline Anticancer Drugs Product Portfolio
- 4.6.5 Pfizer Recent Developments
- 4.7 Jinyuan Pharmaceutical
- 4.7.1 Jinyuan Pharmaceutical Company Information
- 4.7.2 Jinyuan Pharmaceutical Business Overview
- 4.7.3 Jinyuan Pharmaceutical Anthracycline Anticancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Jinyuan Pharmaceutical Anthracycline Anticancer Drugs Product Portfolio
- 4.7.5 Jinyuan Pharmaceutical Recent Developments
- 4.8 Lingnan Pharmaceutical
- 4.8.1 Lingnan Pharmaceutical Company Information
- 4.8.2 Lingnan Pharmaceutical Business Overview
- 4.8.3 Lingnan Pharmaceutical Anthracycline Anticancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Lingnan Pharmaceutical Anthracycline Anticancer Drugs Product Portfolio
- 4.8.5 Lingnan Pharmaceutical Recent Developments
- 4.9 Pude Pharmaceutical
- 4.9.1 Pude Pharmaceutical Company Information
- 4.9.2 Pude Pharmaceutical Business Overview
- 4.9.3 Pude Pharmaceutical Anthracycline Anticancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Pude Pharmaceutical Anthracycline Anticancer Drugs Product Portfolio
- 4.9.5 Pude Pharmaceutical Recent Developments
- 4.10 CSPC OUYI Pharmaceutical
- 4.10.1 CSPC OUYI Pharmaceutical Company Information
- 4.10.2 CSPC OUYI Pharmaceutical Business Overview
- 4.10.3 CSPC OUYI Pharmaceutical Anthracycline Anticancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 CSPC OUYI Pharmaceutical Anthracycline Anticancer Drugs Product Portfolio
- 4.10.5 CSPC OUYI Pharmaceutical Recent Developments
- 4.11 Main Luck Pharmaceuticals
- 4.11.1 Main Luck Pharmaceuticals Company Information
- 4.11.2 Main Luck Pharmaceuticals Business Overview
- 4.11.3 Main Luck Pharmaceuticals Anthracycline Anticancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Main Luck Pharmaceuticals Anthracycline Anticancer Drugs Product Portfolio
- 4.11.5 Main Luck Pharmaceuticals Recent Developments
- 4.12 New Time Pharmaceutical
- 4.12.1 New Time Pharmaceutical Company Information
- 4.12.2 New Time Pharmaceutical Business Overview
- 4.12.3 New Time Pharmaceutical Anthracycline Anticancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 New Time Pharmaceutical Anthracycline Anticancer Drugs Product Portfolio
- 4.12.5 New Time Pharmaceutical Recent Developments
5 Global Anthracycline Anticancer Drugs Market Scenario by Region
- 5.1 Global Anthracycline Anticancer Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Anthracycline Anticancer Drugs Sales by Region: 2021-2032
- 5.2.1 Global Anthracycline Anticancer Drugs Sales by Region: 2021-2026
- 5.2.2 Global Anthracycline Anticancer Drugs Sales by Region: 2027-2032
- 5.3 Global Anthracycline Anticancer Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Anthracycline Anticancer Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Anthracycline Anticancer Drugs Revenue by Region: 2027-2032
- 5.4 North America Anthracycline Anticancer Drugs Market Facts & Figures by Country
- 5.4.1 North America Anthracycline Anticancer Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Anthracycline Anticancer Drugs Sales by Country (2021-2032)
- 5.4.3 North America Anthracycline Anticancer Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Anthracycline Anticancer Drugs Market Facts & Figures by Country
- 5.5.1 Europe Anthracycline Anticancer Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Anthracycline Anticancer Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Anthracycline Anticancer Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Anthracycline Anticancer Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Anthracycline Anticancer Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Anthracycline Anticancer Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Anthracycline Anticancer Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Anthracycline Anticancer Drugs Market Facts & Figures by Country
- 5.7.1 South America Anthracycline Anticancer Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Anthracycline Anticancer Drugs Sales by Country (2021-2032)
- 5.7.3 South America Anthracycline Anticancer Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Anthracycline Anticancer Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Anthracycline Anticancer Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Anthracycline Anticancer Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Anthracycline Anticancer Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Anthracycline Anticancer Drugs Sales by Type (2021-2032)
- 6.1.1 Global Anthracycline Anticancer Drugs Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Anthracycline Anticancer Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Anthracycline Anticancer Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Anthracycline Anticancer Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Anthracycline Anticancer Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Anthracycline Anticancer Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Anthracycline Anticancer Drugs Sales by Application (2021-2032)
- 7.1.1 Global Anthracycline Anticancer Drugs Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Anthracycline Anticancer Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Anthracycline Anticancer Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Anthracycline Anticancer Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Anthracycline Anticancer Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Anthracycline Anticancer Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Anthracycline Anticancer Drugs Value Chain Analysis
- 8.1.1 Anthracycline Anticancer Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Anthracycline Anticancer Drugs Production Mode & Process
- 8.2 Anthracycline Anticancer Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Anthracycline Anticancer Drugs Distributors
- 8.2.3 Anthracycline Anticancer Drugs Customers
9 Global Anthracycline Anticancer Drugs Analyzing Market Dynamics
- 9.1 Anthracycline Anticancer Drugs Industry Trends
- 9.2 Anthracycline Anticancer Drugs Industry Drivers
- 9.3 Anthracycline Anticancer Drugs Industry Opportunities and Challenges
- 9.4 Anthracycline Anticancer Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst